Agonist
Back to library
HealingSubcutaneous

ARA-290

Also known as: Cibinetide · Pyroglutamate Helix B Surface Peptide

11-amino-acid peptide derived from the helix B region of erythropoietin. Activates the innate repair receptor (β common/EPOR heterocomplex) without erythropoietic effects. Anti-inflammatory and neuroprotective in sarcoidosis-associated small fiber neuropathy trials.

At a glance

Half-life
2 hours
Common route
Subcutaneous
Typical dose range
1,000–4,000mcg
Stability (reconstituted)
30days refrigerated

Best timing

Once daily for 4–12 week protocols. Trial dosing was 4 mg subq daily for 28 days in neuropathy populations.

Contraindications

  • Pregnancy
  • Active malignancy (theoretical EPOR signaling concern)
  • Limited long-term safety data

Watch symptoms

  • Mild injection site reaction
  • Headache
  • Minimal hematocrit change (lacks classical EPO effect)
  • Reported neuropathic pain reduction may take 2–4 weeks

Citations

The primary literature.

  1. 01Cibinetide (ARA 290) improves symptoms and signs of sarcoidosis-associated small fiber neuropathyPubMed
  2. 02ARA 290, a peptide derived from erythropoietin, attenuates inflammatory and neuropathic painPubMed
Back to library